What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  HR 0.67 [0.41, 1.07]
  2 studies · 157 participants
  Moderate

Intervention not reported

The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  HR 0.55 [0.35, 0.86]
  2 studies · 157 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  RR 0.61 [0.16, 2.22]
  2 studies · 157 participants
  Moderate

Intervention not reported

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  GRADE not reported

Intervention not reported

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Intervention not reported

The intervention showed no clear difference in overall survival (moderate certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  HR 0.97 [0.76, 1.22]
  3 studies · 701 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in treatment‐related mortality (moderate certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  RR 1.28 [0.25, 6.61]
  4 studies · 941 participants
  Moderate

Intervention not reported

The intervention probably leads to lower progression‐free survival (moderate certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  HR 0.42 [0.33, 0.54]
  3 studies · 540 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in secondary malignancies AML/MDS (low certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  RR 2.87 [0.7, 11.75]
  4 studies · 1023 participants
  Low

Intervention not reported

The intervention showed no clear difference in secondary malignancies Solid cancer (low certainty).

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  RR 1.2 [0.25, 5.77]
  3 studies · 701 participants
  Low

Intervention not reported

• High‐dose therapy with autologous stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular… 2012 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 527 participants
  Very low